{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T06:51:14Z","timestamp":1776408674374,"version":"3.51.2"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-06923-3","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:17:34Z","timestamp":1773796654000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Burden of disease for multiple myeloma in China and the Asia\u2013Pacific region, 1990\u20132021: a systematic analysis of the Global Burden of Disease (GBD) 2021 study"],"prefix":"10.1007","volume":"105","author":[{"given":"Sen-Xin","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ni","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xun-Ru","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-Ping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"issue":"1","key":"6923_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A (2024) Cancer statistics, 2024. CA Cancer J Clin 74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"6923_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.hoc.2023.12.010","volume":"38","author":"F Maura","year":"2024","unstructured":"Maura F, Bergsagel PL (2024) Molecular pathogenesis of multiple myeloma: clinical implications. Hematol Oncol Clin North Am 38(2):267\u2013279. https:\/\/doi.org\/10.1016\/j.hoc.2023.12.010","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"6923_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s43556-024-00188-w","volume":"5","author":"Q Lu","year":"2024","unstructured":"Lu Q, Yang D, Li H, Niu T, Tong A (2024) Multiple myeloma: signaling pathways and targeted therapy. Mol Biomed 5(1):25. https:\/\/doi.org\/10.1186\/s43556-024-00188-w","journal-title":"Mol Biomed"},{"issue":"1","key":"6923_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/medsci9010003","volume":"9","author":"SA Padala","year":"2021","unstructured":"Padala SA, Barsouk A, Barsouk A et al (2021) Epidemiology, staging, and management of multiple myeloma. Med Sci 9(1):3. https:\/\/doi.org\/10.3390\/medsci9010003","journal-title":"Med Sci"},{"issue":"9","key":"6923_CR5","doi-asserted-by":"publisher","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","volume":"9","author":"J Huang","year":"2022","unstructured":"Huang J, Chan SC, Lok V et al (2022) The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends. Lancet Haematol 9(9):e670\u2013e677. https:\/\/doi.org\/10.1016\/S2352-3026(22)00165-X","journal-title":"Lancet Haematol"},{"issue":"1","key":"6923_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00529-7","volume":"10","author":"F Malard","year":"2024","unstructured":"Malard F, Neri P, Bahlis NJ et al (2024) Multiple myeloma. Nat Rev Dis Primers 10(1):45. https:\/\/doi.org\/10.1038\/s41572-024-00529-7","journal-title":"Nat Rev Dis Primers"},{"issue":"9","key":"6923_CR7","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00359-2","volume":"10","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV, Kumar S (2020) Multiple myeloma current treatment algorithms. Blood Cancer J 10(9):94. https:\/\/doi.org\/10.1038\/s41408-020-00359-2","journal-title":"Blood Cancer J"},{"issue":"9","key":"6923_CR8","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV (2024) Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol 99(9):1802\u20131824. https:\/\/doi.org\/10.1002\/ajh.27422","journal-title":"Am J Hematol"},{"issue":"4","key":"6923_CR9","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.2024024371","volume":"144","author":"O Landgren","year":"2024","unstructured":"Landgren O, Prior TJ, Masterson T et al (2024) EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood 144(4):359\u2013367. https:\/\/doi.org\/10.1182\/blood.2024024371","journal-title":"Blood"},{"issue":"2","key":"6923_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s11899-021-00633-5","volume":"16","author":"L Bertamini","year":"2021","unstructured":"Bertamini L, D\u2019Agostino M, Gay F (2021) MRD assessment in multiple myeloma: progress and challenges. Curr Hematol Malig Rep 16(2):162\u2013171. https:\/\/doi.org\/10.1007\/s11899-021-00633-5","journal-title":"Curr Hematol Malig Rep"},{"issue":"10","key":"6923_CR11","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1080\/10428194.2024.2358857","volume":"65","author":"QQ Cui","year":"2024","unstructured":"Cui QQ, Li ZH, Ma YP (2024) MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma. Leuk Lymphoma 65(10):1430\u20131437. https:\/\/doi.org\/10.1080\/10428194.2024.2358857","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"6923_CR12","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M et al (2022) Diagnosis and management of multiple myeloma: a review. JAMA 327(5):464\u2013477. https:\/\/doi.org\/10.1001\/jama.2022.0003","journal-title":"JAMA"},{"issue":"1","key":"6923_CR13","doi-asserted-by":"publisher","first-page":"7","DOI":"10.23736\/S0031-0808.20.04145-2","volume":"63","author":"M Gentile","year":"2021","unstructured":"Gentile M, Morabito F, Martino M et al (2021) Chemotherapy-based regimens in multiple myeloma in 2020. Panminerva Med 63(1):7\u201312. https:\/\/doi.org\/10.23736\/S0031-0808.20.04145-2","journal-title":"Panminerva Med"},{"issue":"12","key":"6923_CR14","doi-asserted-by":"publisher","first-page":"e943","DOI":"10.1016\/S2468-2667(23)00211-6","volume":"8","author":"J Qi","year":"2023","unstructured":"Qi J, Li M, Wang L et al (2023) National and subnational trends in cancer burden in China, 2005-20: an analysis of national mortality surveillance data. Lancet Public Health 8(12):e943\u2013e955. https:\/\/doi.org\/10.1016\/S2468-2667(23)00211-6","journal-title":"Lancet Public Health"},{"key":"6923_CR15","unstructured":"United Nations Economic and Social Commission for Asia and the Pacific. Addressing the challenges of population ageing in Asia and the Pacific [Internet]. Bangkok: UN ESCAP; 2023 [cited 2026 Jan 16]. Available from: https:\/\/www.unescap.org"},{"key":"6923_CR16","unstructured":"Mao, Yun, et al. (2024) Cancer Burden in Asia, 1990\u20132021: A Systematic Analysis for the Global Burden of Disease Study 2021. SSRN. https:\/\/ssrn.com\/abstract=5574665"},{"issue":"1","key":"6923_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-024-00649-y","volume":"12","author":"Y Zhou","year":"2024","unstructured":"Zhou Y, Huang G, Cai X, Liu Y, Qian B, Li D (2024) Global, regional, and national burden of acute myeloid leukemia, 1990-2021: a systematic analysis for the global burden of disease study 2021. Biomark Res 12(1):101. https:\/\/doi.org\/10.1186\/s40364-024-00649-y","journal-title":"Biomark Res"},{"key":"6923_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1609692","volume":"12","author":"X Miao","year":"2025","unstructured":"Miao X, Wang Z, Wang H et al (2025) Global, regional, and national burden of multiple myeloma, 1990 to 2021 and predictions to 2035: an analysis of the Global Burden of Disease Study 2021. Front Med (Lausanne) 12:1609692. https:\/\/doi.org\/10.3389\/fmed.2025.1609692","journal-title":"Front Med (Lausanne)"},{"issue":"10440","key":"6923_CR19","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/S0140-6736(24)00757-8","volume":"403","author":"GBD 2021 Diseases and Injuries Collaborators","year":"2024","unstructured":"GBD 2021 Diseases and Injuries Collaborators (2024) Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 403(10440):2133\u20132161. https:\/\/doi.org\/10.1016\/S0140-6736(24)00757-8","journal-title":"Lancet"},{"issue":"10440","key":"6923_CR20","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/S0140-6736(24)00933-4","volume":"403","author":"GBD 2021 Risk Factors Collaborators","year":"2024","unstructured":"GBD 2021 Risk Factors Collaborators (2024) Global burden and strength of evidence for 88 risk factors in 204 countries and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 403(10440):2162\u20132203. https:\/\/doi.org\/10.1016\/S0140-6736(24)00933-4","journal-title":"Lancet"},{"key":"6923_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217440","author":"X Dou","year":"2025","unstructured":"Dou X, Duan G, Zhong Y et al (2025) The burden of multiple myeloma in China: trends from 1990 to 2021 and forecasts for 2050. Cancer Lett. https:\/\/doi.org\/10.1016\/j.canlet.2025.217440","journal-title":"Cancer Lett"},{"issue":"6","key":"6923_CR22","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.ccell.2023.05.007","volume":"41","author":"M Dang","year":"2023","unstructured":"Dang M, Wang R, Lee HC et al (2023) Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease. Cancer Cell 41(6):1032-1047.e4. https:\/\/doi.org\/10.1016\/j.ccell.2023.05.007","journal-title":"Cancer Cell"},{"issue":"1","key":"6923_CR23","doi-asserted-by":"publisher","first-page":"8","DOI":"10.6004\/jnccn.2022.0002","volume":"20","author":"NS Callander","year":"2022","unstructured":"Callander NS, Baljevic M, Adekola K et al (2022) NCCN guidelines\u00ae insights: multiple myeloma, version 3.2022. J Natl Compr Canc Netw 20(1):8\u201319. https:\/\/doi.org\/10.6004\/jnccn.2022.0002","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"6923_CR24","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1002\/ajh.26512","volume":"97","author":"U Goel","year":"2022","unstructured":"Goel U, Usmani S, Kumar S (2022) Current approaches to management of newly diagnosed multiple myeloma. Am J Hematol 97(1):S3\u2013S25. https:\/\/doi.org\/10.1002\/ajh.26512","journal-title":"Am J Hematol"},{"issue":"8354","key":"6923_CR25","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/s0140-6736(83)90739-0","volume":"2","author":"TJ McElwain","year":"1983","unstructured":"McElwain TJ, Powles RL (1983) High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 2(8354):822\u2013824. https:\/\/doi.org\/10.1016\/s0140-6736(83)90739-0","journal-title":"Lancet"},{"issue":"10","key":"6923_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004626.pub3","volume":"10","author":"F Naumann-Winter","year":"2012","unstructured":"Naumann-Winter F, Greb A, Borchmann P, Bohlius J, Engert A, Schnell R (2012) First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Cochrane Database Syst Rev 10(10):CD004626. https:\/\/doi.org\/10.1002\/14651858.CD004626.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"6923_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00645-1","volume":"12","author":"AH Bazarbachi","year":"2022","unstructured":"Bazarbachi AH, Al Hamed R, Malard F, Bazarbachi A, Harousseau JL, Mohty M (2022) Induction therapy prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma: an update. Blood Cancer J 12(3):47. https:\/\/doi.org\/10.1038\/s41408-022-00645-1","journal-title":"Blood Cancer J"},{"issue":"10","key":"6923_CR28","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1358\/dot.2021.57.10.331385","volume":"57","author":"SR Goldsmith","year":"2021","unstructured":"Goldsmith SR, Foley N, Schroeder MA (2021) Daratumumab for the treatment of multiple myeloma. Drugs Today (Barc) 57(10):591\u2013605. https:\/\/doi.org\/10.1358\/dot.2021.57.10.331385","journal-title":"Drugs Today (Barc)"},{"issue":"4","key":"6923_CR29","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1182\/blood.2023021221","volume":"143","author":"L Rasche","year":"2024","unstructured":"Rasche L, Hudecek M, Einsele H (2024) CAR T-cell therapy in multiple myeloma: mission accomplished? Blood 143(4):305\u2013310. https:\/\/doi.org\/10.1182\/blood.2023021221","journal-title":"Blood"},{"issue":"1","key":"6923_CR30","doi-asserted-by":"publisher","first-page":"e70039","DOI":"10.1002\/hon.70039","volume":"43","author":"EA Martino","year":"2025","unstructured":"Martino EA, Palmieri S, Galli M et al (2025) Elotuzumab plus pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials. Hematol Oncol. 43(1):e70039. https:\/\/doi.org\/10.1002\/hon.70039","journal-title":"Hematol Oncol."},{"issue":"4","key":"6923_CR31","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s00277-019-03602-4","volume":"98","author":"VTM Hungria","year":"2019","unstructured":"Hungria VTM, Lee JH, Maiolino A et al (2019) Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. Ann Hematol 98(4):941\u2013949. https:\/\/doi.org\/10.1007\/s00277-019-03602-4","journal-title":"Ann Hematol"},{"issue":"13","key":"6923_CR32","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1002\/cncr.34760","volume":"129","author":"SJ Grant","year":"2023","unstructured":"Grant SJ, Wildes TM, Rosko AE, Silberstein J, Giri S (2023) A real-world data analysis of predictors of early mortality after a diagnosis of multiple myeloma. Cancer 129(13):2023\u20132034. https:\/\/doi.org\/10.1002\/cncr.34760","journal-title":"Cancer"},{"issue":"4","key":"6923_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13040666","volume":"13","author":"C Geng","year":"2023","unstructured":"Geng C, Yang G, Zhou H et al (2023) Characteristics and risk factors of ultra-high-risk patients with newly diagnosed multiple myeloma. J Pers Med 13(4):666. https:\/\/doi.org\/10.3390\/jpm13040666","journal-title":"J Pers Med"},{"key":"6923_CR34","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3176","volume":"370","author":"UA Shah","year":"2020","unstructured":"Shah UA, Mailankody S (2020) Emerging immunotherapies in multiple myeloma. BMJ 370:m3176. https:\/\/doi.org\/10.1136\/bmj.m3176","journal-title":"BMJ"},{"issue":"2","key":"6923_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70192","volume":"132","author":"KL Ong","year":"2026","unstructured":"Ong KL, Arnold KD, Wessel MC et al (2026) Sex differences in the clinical presentation of patients with newly diagnosed multiple myeloma. Cancer 132(2):e70192. https:\/\/doi.org\/10.1002\/cncr.70192","journal-title":"Cancer"},{"issue":"3","key":"6923_CR36","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1158\/1055-9965.EPI-14-1145","volume":"24","author":"G Andreotti","year":"2015","unstructured":"Andreotti G, Birmann BM, Cozen W et al (2015) A pooled analysis of cigarette smoking and risk of multiple myeloma from the international multiple myeloma consortium. Cancer Epidemiol Biomarkers Prev 24(3):631\u2013634. https:\/\/doi.org\/10.1158\/1055-9965.EPI-14-1145","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"6","key":"6923_CR37","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN (2023) Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol 20(6):359\u2013371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06923-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-06923-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-06923-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:59:00Z","timestamp":1776405540000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-06923-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":37,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["6923"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-06923-3","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}